GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Addex Therapeutics Ltd (XSWX:ADXN) » Definitions » EV-to-EBITDA

Addex Therapeutics (XSWX:ADXN) EV-to-EBITDA : -0.49 (As of May. 16, 2024)


View and export this data going back to 2007. Start your Free Trial

What is Addex Therapeutics EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Addex Therapeutics's enterprise value is CHF5.05 Mil. Addex Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-10.23 Mil. Therefore, Addex Therapeutics's EV-to-EBITDA for today is -0.49.

The historical rank and industry rank for Addex Therapeutics's EV-to-EBITDA or its related term are showing as below:

XSWX:ADXN' s EV-to-EBITDA Range Over the Past 10 Years
Min: -16.22   Med: -0.74   Max: 0.39
Current: -0.49

During the past 13 years, the highest EV-to-EBITDA of Addex Therapeutics was 0.39. The lowest was -16.22. And the median was -0.74.

XSWX:ADXN's EV-to-EBITDA is ranked worse than
100% of 457 companies
in the Biotechnology industry
Industry Median: 9.79 vs XSWX:ADXN: -0.49

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-16), Addex Therapeutics's stock price is CHF0.0668. Addex Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was CHF-0.140. Therefore, Addex Therapeutics's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Addex Therapeutics EV-to-EBITDA Historical Data

The historical data trend for Addex Therapeutics's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Addex Therapeutics EV-to-EBITDA Chart

Addex Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.88 -2.88 -1.30 -0.06 -0.22

Addex Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.06 -0.54 -0.23 -0.19 -0.22

Competitive Comparison of Addex Therapeutics's EV-to-EBITDA

For the Biotechnology subindustry, Addex Therapeutics's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Addex Therapeutics's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Addex Therapeutics's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Addex Therapeutics's EV-to-EBITDA falls into.



Addex Therapeutics EV-to-EBITDA Calculation

Addex Therapeutics's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=5.046/-10.228
=-0.49

Addex Therapeutics's current Enterprise Value is CHF5.05 Mil.
Addex Therapeutics's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-10.23 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Addex Therapeutics  (XSWX:ADXN) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Addex Therapeutics's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0668/-0.140
=At Loss

Addex Therapeutics's share price for today is CHF0.0668.
Addex Therapeutics's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-0.140.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Addex Therapeutics EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Addex Therapeutics's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Addex Therapeutics (XSWX:ADXN) Business Description

Traded in Other Exchanges
Address
Chemin des Aulx 12, Plan-les-Ouates, P.O. Box 68, Geneva, CHE, 1202
Addex Therapeutics Ltd is a biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe.

Addex Therapeutics (XSWX:ADXN) Headlines

From GuruFocus

Enamine Extend Collaboration With Prominent Swiss Biotech

By Business Wire Business Wire 02-24-2021